Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Polycystic Ovary Syndrome × Tablets × Clear all

Phase

Phase NA 4 Phase 2/3 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 9 Multiple Myeloma 3 Melanoma 3 Venous Thromboembolism 1 Triple Negative Breast Neoplasms 1 Thrombocythemia, Essential 1 Stem Cell Transplant Complications 1 Skin Toxicity 1 Skin Neoplasms 1 Resectable Pancreatic Ductal Adenocarcinoma 1 Renal Insufficiency 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Polycystic Ovary Syndrome 1 Obesity 1 Neoplasms 1 Myeloproliferative Disorders 1 Meningioma 1 Lymphoma, Mantle-Cell 1 Lung Neoplasms 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, B-Cell 1 Leukemia 1 Inflammation 1 Head and Neck Neoplasms 1

Interventions

Metformin 7 Clomiphene 6 maltodextrin 2 artenimol 2 Sugars 2 Orlistat 2 Inositol 2 Contraceptives, Oral 2 Cholecalciferol 2 salicylsalicylic acid 1 licogliflozin 1 follitropin alfa 1 elagolix 1 Vitamin E 1 Vitamin D 1 Thioctic Acid 1 Tablets 1 Spironolactone 1 Sodium Salicylate 1 Resveratrol 1 Pioglitazone 1 Pentoxifylline 1 Ovulation Induction 1 Linseed Oil 1 Leuprolide 1 Letrozole 1 Inulin 1 Interleukin 1 Receptor Antagonist Protein 1 Gonadotropins 1 Folic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03259919 2018-10-18

pilPregMet

Norwegian University of Science and Technology

Phase 2 Completed

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡